This Article Abstract Full Text (PDF) All Versions of this Article: 108/20/2453    most recent 01.CIR.0000099509.76044.A2v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Blankenberg, S. Search for Related Content PubMed PubMed Citation Articles by Blankenberg, S. Pubmed/NCBI databases Gene GEO Profiles HomoloGene OMIM UniGene Substance via MeSH Related Collections Pathophysiology Risk Factors Chronic ischemic heart disease Epidemiology

(Circulation. 2003;108:2453.)
© 2003 American Heart Association, Inc.

Clinical Investigation and Reports

Interleukin-18 and the Risk of Coronary Heart Disease in European Men

The Prospective Epidemiological Study of Myocardial Infarction (PRIME)

Stefan Blankenberg, MD; Gérald Luc, MD, PhD; Pierre Ducimetière, PhD; Dominique Arveiler, MD; Jean Ferrières, MD, MSc; Philippe Amouyel, MD, PhD; Alun Evans, MD, FRCP; François Cambien, MD; Laurence Tiret, PhD, on behalf of the PRIME Study Group

From INSERM U525 (S.B., F.C., L.T.), Faculté de Médecine Pitié-Salpétrière, Paris, France; Department of Medicine II (S.B.), Johannes Gutenberg-University Mainz, Germany; INSERM U545 (G.L.), Department of Atherosclerosis, Pasteur Institute, Lille, France; INSERM U258 (P.D.), Villejuif, France; Department of Epidemiology and Public Health (D.A.), Faculty of Medicine, Strasbourg, France; INSERM U558 (J.F.), Department of Epidemiology, Toulouse, France; INSERM U508 (P.A.), Pasteur Institute, Lille, France; and Department of Epidemiology and Public Health (A.E.), Queen’s University Belfast, Belfast, Northern Ireland.

Correspondence to Dr Stefan Blankenberg, Department of Medicine II, Johannes Gutenberg-University Mainz, Langenbeckstraße 1, 55131 Mainz, Germany. E-mail stefan.blankenberg{at}uni-mainz.de

Received June 9, 2003; de novo received August 8, 2003; revision received September 16, 2003; accepted September 18, 2003.

	Abstract

Top Abstract Introduction Methods Results Discussion Appendix References

 
Background— Interleukin (IL)-18 promotes atherosclerotic plaque growth and vulnerability. It is unknown, however, whether elevations of circulating IL-18 precede the onset of coronary events in apparently healthy individuals.

Methods and Results— We evaluated the relationship between baseline plasma levels of IL-18 and the subsequent incidence of coronary events over a 5-year follow-up in the Prospective Epidemiological Study of Myocardial Infarction (PRIME),which included 10 600 healthy European men aged 50 to 59 years at baseline. Analysis was performed in a nested case-control manner comparing 335 cases with a coronary event to 670 age-matched controls. Baseline levels of IL-18 were significantly higher in men who developed a coronary event than in controls (225.1 versus 203.9 pg/mL, P=0.005). After adjustment for most potential confounders, including C-reactive protein, IL-6, and fibrinogen, the relative risk of future coronary events associated with increasing tertiles of IL-18 was 1.65 (95% CI 1.14 to 2.40, P=0.008) in Northern Ireland, 1.29 (95% CI 0.96 to 1.73, P=0.09) in France, and 1.42 (95% CI 1.13 to 1.79, P=0.003) in both populations combined (P=0.31 for the test of homogeneity between populations). In all models, IL-18 made an independent contribution to the prediction of risk over lipids or other inflammatory markers such as C-reactive protein, IL-6, or fibrinogen.

Conclusions— Plasma IL-18 level was identified as an independent predictor of coronary events in healthy, middle-aged European men. Determination of circulating IL-18 might improve the prediction of coronary events.

Key Words: inflammation • cardiovascular diseases • myocardial infarction • prognosis • interleukins

	Introduction

Top Abstract Introduction Methods Results Discussion Appendix References

 
With the recognition that atherosclerosis is intimately associated with an inflammatory process,¹ plasma markers of inflammation have been evaluated as potential tools for cardiovascular risk prediction.² Among these, C-reactive protein (CRP) and fibrinogen have been evaluated most extensively and have been shown to be predictive for future coronary events.^3,4 The clinical usefulness of CRP has been discussed recently.⁵ However, comparative data between single inflammatory predictors are sparse,⁶ and the issue has to be addressed as to whether some inflammatory markers are superior to others or add complementary information by simultaneous determination. Interleukin (IL)-18 is a pleiotropic proinflammatory cytokine and plays a central role in the inflammatory cascade.⁷ Originally, it was identified as an interferon-–inducing factor,⁸ stimulating interferon- production in T lymphocytes and natural killer cells, which are ascribed a key role in atherosclerotic plaque rupture.^9,10

Recently, evidence from experimental studies has emerged that expression of IL-18 is intimately related to atherosclerotic plaque progression and vulnerability.^11–14 These results could be translated into the clinical setting, as shown in the AtheroGene Study, which suggested that the concentration of circulating IL-18 was one of the strongest predictors of future cardiovascular events in patients with stable and unstable angina.¹⁵ To extend these results toward a primary prevention setting, we aimed to evaluate the ability of circulating levels of IL-18 to predict future coronary events in a large, population-based cohort of initially healthy European men.

	Methods

Top Abstract Introduction Methods Results Discussion Appendix References

 
Study Population
The design of the Prospective Epidemiological Study of Myocardial Infarction (PRIME) is described elsewhere.¹⁶ PRIME is a population-based prospective study of coronary events. During the 1991 to 1994 recruitment period, 10 600 men aged 50 to 59 years living in the areas of Lille, Strasbourg, and Toulouse in France and Belfast, Northern Ireland, were examined. The entry examination included standardized questionnaires relating to medical history, drug intake, presence of coronary heart disease (CHD), and various habits, including tobacco and alcohol consumption. Approval from the appropriate local research ethics committee was obtained, and all subjects gave written informed consent.

During the 5-year follow-up, subjects were contacted annually by letter and, if necessary, by telephone, and a clinical event questionnaire was completed. For all possible events, clinical information was sought directly from hospital or general practitioners’ notes. All details of ECG, hospital admissions, enzymes, surgical operations, angioplasty, and treatment were collected and classified according to MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) criteria.¹⁷ Death certificates were used for supporting information on cause of death. After 5 years, follow-up was achieved in >98% of the cohort.

Outcome was defined by a combined end point that included hard coronary events (nonfatal myocardial infarction [MI] and coronary deaths) and angina pectoris. Angina pectoris was defined by the presence of chest pain at rest or on exertion and 1 of the following criteria: (1) angiographic stenosis greater than 50%; (2) a positive scintigraphy (if no angiographic data); (3) a positive exercise stress test (if no angiographic or scintigraphic data); or (4) ECG changes at rest but without any set of conditions for MI and no evidence of a noncoronary cause in the clinical history. Unstable angina was defined according to the Braunwald criteria. In the absence of ECG or enzyme data, the diagnosis was rejected. Full details on the determination of these end points have been described previously.¹⁸ All events were checked by a medical committee to provide independent validation of the event.

Laboratory Methods
Blood was drawn into EDTA tubes after a 12-hour fast. Samples were stored in liquid nitrogen until analysis. Plasma IL-18 was measured by single determination with a commercially available ELISA method (MBL Co, Ltd). The within-run coefficients of variation were determined to be 3.2% at a mean of 218.5 pg/mL (7 samples) and 8.9% at a mean of 518.9 pg/mL (7 samples); between-run coefficients of variation were 3.2% at 218.5 pg/mL (7 samples) and 8.1% at 290.1 pg/mL (7 samples). Samples for these methodological analyses were taken from the German AtheroGene study population. To directly compare the concentrations between the AtheroGene Study¹⁵ and the PRIME study, the absolute values for IL-18 in AtheroGene have to be multiplied by a factor of 5 because of different dilution procedures. Concentrations of IL-18 did not differ regardless of whether they were determined in serum or plasma (data not shown). CRP was measured by immunonephelometry (Dade Behring), IL-6 by ELISA (R&D Systems), and fibrinogen by the Clauss method. Lipids were determined by routine methods.

Statistical Analysis
The present study was conducted in a nested case-control sample that included all cases with a coronary event (n=335) and 2 matched controls for each case (n=670). Controls were age-matched (±3 years) participants recruited in the same center and on the same day (±3 days) as the corresponding case and were free of CHD at the date of the coronary event of the case. Mean levels of continuous variables were compared between cases and controls by ANOVA adjusted for population. Variables with a skewed distribution were log transformed for analysis. Conditional logistic regression analysis for matched case-control studies was used to investigate the association between outcome and explanatory variables. In these analyses, IL-18 and other inflammatory markers were treated in tertiles derived from the distribution of control individuals from the 2 populations pooled. Three models were considered for testing IL-18 effect: (1) unadjusted; (2) adjusted for classic risk factors (body mass index [BMI], smoking status, diabetes, hypertension, total cholesterol, HDL cholesterol, and triglycerides); and (3) additionally adjusted for inflammatory markers (CRP, fibrinogen, and IL-6). The relative risk (RR) associated with increasing tertiles of IL-18 was estimated by considering the tertiles as an ordinal variable (coded 0, 1, or 2). Homogeneity of the effect of IL-18 between populations was tested by introducing an interaction term in the model. RRs and 95% CIs are reported. P<0.05 was considered significant. All computations were performed with SAS software, version 8.1 (SAS Institute).

	Results

Top Abstract Introduction Methods Results Discussion Appendix References

 
Baseline Characteristics
Baseline characteristics of cases and controls are reported in Table 1. As expected, men who developed an incident coronary event were more likely to have a higher prevalence of classic risk factors than their matched controls and had higher baseline levels of inflammatory markers (CRP, fibrinogen, and IL-6), as already reported.¹⁹

View this table: [in this window] [in a new window]   TABLE 1. Baseline Characteristics of PRIME Study Participants

Correlates of IL-18 Compared With Other Inflammatory Markers
As outlined in Table 2, smoking status strongly affected concentrations of CRP, fibrinogen, and IL-6. Hypertension was also associated with elevated levels of CRP and IL-6, whereas diabetes mostly related to IL-6 levels. In contrast, the concentration of IL-18 was independent of any of these factors. Moreover, unlike the acute-phase reactants, IL-18 levels did not correlate with age or BMI (Table 3). The negative correlation of IL-18 with HDL cholesterol was of similar magnitude to that observed for the other inflammatory markers. IL-18 concentrations did not correlate with fibrinogen levels and showed only a modest correlation with CRP and IL-6. This was in sharp contrast with the strong associations observed within the cluster of the 3 acute-phase reactants. There was no association between IL-18 levels and lipid-lowering drugs, ACE inhibitors, or ß-blockers (data not shown).

View this table: [in this window] [in a new window]   TABLE 2. Mean Levels of Inflammatory Markers According to Categorical Risk Factors

View this table: [in this window] [in a new window]   TABLE 3. Pearson Correlation Coefficients Between Inflammatory Markers and Continuous Risk Factors

IL-18 and Coronary Risk
Baseline concentrations of IL-18 were significantly higher among patients who experienced a coronary event during follow-up than among those who did not (225.1 versus 203.9 pg/mL; P=0.005). The unadjusted RRs for the combined coronary end point were 1.32 (95% CI 0.90 to 1.93, P=0.16) in the second tertile and 2.07 (95% CI 1.40 to 3.05, P<0.001) in the third tertile compared with the first tertile of IL-18. These unadjusted RRs were of similar magnitude to those associated with tertiles of CRP and fibrinogen and lower than those associated with IL-6 (Figure 1). However, adjustment for cardiovascular risk factors significantly attenuated the relationship between coronary risk and CRP, fibrinogen, and IL-6. Conversely, the association between IL-18 and outcome remained unaffected by adjustment on risk factors and by further adjustment on CRP taken as representative of the acute-phase reactants cluster (Figure 1).

View larger version (19K): [in this window] [in a new window]   Figure 1. RRs for combined coronary events according to tertiles of IL-18, IL-6, CRP, and fibrinogen. Tertiles were derived from control distribution. Lowest tertile serves as reference group. Gray squares (model 1) indicate crude RRs; black diamonds (model 2) indicate RRs adjusted for BMI, smoking status, diabetes, hypertension, total cholesterol, HDL cholesterol, and triglycerides; gray circles (model 3) indicate RRs further adjusted for CRP (in case of IL-18) or IL-18 (in case of IL-6, CRP, and fibrinogen).

Circulating levels of IL-18 were higher in Northern Ireland than in France (218.1 versus 188.9 pg/mL in controls, P<0.001; 262.7 versus 196.2 pg/mL in cases, P<0.001). This observation was in accordance with similar differences observed for the other inflammatory markers (CRP, fibrinogen, and IL-6) and for lipid factors (data not shown). These differences paralleled that of the prevalence of CHD between the 2 countries.

The association between increasing IL-18 tertiles and coronary risk appeared stronger in Northern Ireland (RR=1.65, 95% CI 1.14 to 2.40, P for trend=0.008) than in France (RR=1.29, 95% CI 0.96 to 1.73, P for trend=0.09), although the 2 RRs were not statistically different (Figure 2A). The RR associated with increasing tertiles of IL-18 was 1.42 (95% CI 1.13 to 1.79, P=0.003) in both countries combined. When we separately analyzed MI/coronary death (Figure 2B) and angina pectoris (Figure 2C), the association appeared to be stronger for angina pectoris (RR=1.79, 95% CI 1.23 to 2.61, P for trend=0.003) than for MI/coronary death (RR=1.38, 95% CI 0.98 to 1.93, P for trend=0.06), but again, the difference between the 2 RRs did not reach statistical significance (P=0.31 for the test of homogeneity).

View larger version (19K): [in this window] [in a new window]   Figure 2. RRs for coronary event according to tertiles of IL-18, separated by end point and country. Solid squares indicate RRs from both countries pooled, respective symbols RRs from France (F) and Belfast (B). All RRs are fully adjusted (see model 3, Figure 1). A, Combined end point (P for trend=0.003 in both countries pooled, P=0.31 for homogeneity between countries). B, Coronary death/MI (P for trend=0.06, P=0.48 for homogeneity). C, Angina pectoris (P for trend=0.003, P=0.35 for homogeneity).

Risk Prediction of IL-18 Beyond Lipid and Classic Inflammatory Variables
We further explored to what extent IL-18 might add to the predictive value of the strongest classic lipid predictor (total cholesterol/HDL cholesterol ratio) or of the inflammatory markers (Table 4). In these analyses, subjects were classified as being below or above the median for any of the risk factors considered (medians derived from the distributions of controls). Elevation of IL-18 alone was associated with an RR that ranged from 1.86 to 2.51, which was significant in all cases (Table 4). Furthermore, IL-18 added to the predictive value of the other predictors, as demonstrated by the increase in risk when elevation of IL-18 was associated with another risk factor.

View this table: [in this window] [in a new window]   TABLE 4. RRs of Combined Coronary Events According to Baseline Levels of IL-18 and Total Cholesterol/HDL Cholesterol Ratio, CRP, Fibrinogen, or IL-6 Above (+) or Below (-) the Median (Median of the Control Distribution)

Finally, we investigated which marker, IL-18 or CRP (taken as representative of the acute-phase reactants cluster), was the most predictive of coronary events over lipid testing. IL-18, CRP, and the total cholesterol/HDL cholesterol ratio (all 3 variables dichotomized according to their median value) were introduced simultaneously in a model additionally adjusted for BMI, smoking status, diabetes, and hypertension. The adjusted RRs were 1.65 (95% CI 1.19 to 2.29, P=0.003) for the lipid ratio, 1.63 (95% CI 1.17 to 2.27, P=0.004) for CRP, and 1.82 (95% CI 1.30 to 2.55, P<0.001) for IL-18, respectively.

	Discussion

Top Abstract Introduction Methods Results Discussion Appendix References

 
In this prospective, population-based cohort of healthy European men, baseline plasma level of IL-18 was independently associated with the future development of coronary events. The relationship between IL-18 and the risk of CHD appeared to be independent of classic risk factors and other inflammatory biomarkers. In the present study, subjects in the highest tertile (>235 pg/mL) had a clear elevation of risk compared with those in the lowest tertile (<160 pg/mL). It must be further evaluated from different studies and various clinical settings which cutoff value of IL-18 appears to be the most useful to identify individuals at coronary risk.

Atherothrombosis is a chronic process that implicates responses of innate and acquired immunity.²⁰ Alongside increasing experimental evidence, circulating markers of inflammation have been shown to predict cardiovascular risk in initially healthy people. Among these, CRP appears to be a consistent predictor in men and women across different populations,^21,22 and the clinical usefulness of CRP has been postulated,²³ although its application to clinical practice has been recently discussed.⁵ In the PRIME study, CRP was no longer associated with the risk of coronary events when controlled for IL-6 levels, nor was fibrinogen.¹⁹ In addition to acute-phase reactants, other inflammatory biomarkers have been shown to provide prognostic information in a variety of clinical settings.^15,24–27 Among them, IL-18 enjoys an important place as a regulator of innate and acquired immune responses.⁷ The present results obtained in healthy individuals extend the previous results observed in patients with established coronary artery disease.¹⁵ Epidemiological evidence and emerging experimental data support the hypothesis that the IL-18 receptor/ligand dyad might play a key role in the inflammatory response that contributes to atherosclerotic plaque formation and vulnerability. IL-18 has been identified in human atherosclerotic lesions, with significantly higher levels of IL-18 mRNA in unstable plaques.¹¹ In addition, administration of IL-18 leads to an increase in lesion size and promotes an elevation in the number of lesion-associated T lymphocytes in animal models. Both effects were abolished in interferon-–deficient mice, strongly suggesting the importance of the interferon-–dependent pathway.¹³ Furthermore, inhibition of IL-18 signaling by IL-18 binding protein has been shown to reduce lesion progression and to stabilize plaque composition, with a decrease in inflammatory cells and lipid content and an increase in smooth muscle cells and collagen.¹²

Given the experimental data and the conclusive epidemiological evidence in different clinical settings, IL-18 appears to be an attractive candidate biomarker for clinical use. Indeed, IL-18 adds significant prognostic information over the classic lipid and inflammatory markers. Whereas CRP, fibrinogen, and IL-6 are influenced by classic risk factors, and adjustment for these confounders attenuates the predictive power of these biomarkers, the effect of IL-18 was not attenuated by adjustment for classic risk factors.

Some desirable characteristics of a cardiovascular risk predictor include standardized assays, stability of the biomarker, independence from established risk factors and improved risk prediction over and above them, a wide range of similar results in different populations, and easy application with reasonable costs. These criteria are fulfilled for CRP, although some doubts remain, especially with regard to its utility in patients at high risk or in patients already taking cardiovascular medications. In contrast, IL-18 has been shown to be predictive in initially healthy men in the PRIME study, as well as in patients with established coronary artery disease in the AtheroGene Study,¹⁵ but this marker is not yet ready for clinical application. Assessment of IL-18 is presently an expensive and time-consuming procedure, and before it enters the clinical setting, standardized reproducible assays should be available, as well as a consistent series of results from prospective studies.

A limitation of the present study is that the determination of IL-18 was only performed once on samples that were stored in liquid nitrogen. We therefore cannot exclude the possibility of protein degradation. However, this should affect both cases and controls in a similar way, and the consequence would be an attenuation of the relationship with disease.

In conclusion, in this prospective study of initially healthy men, we demonstrated a strong and independent association between plasma levels of IL-18 and future coronary events. This finding is in accordance with results obtained in high-risk patients and supports the concept, already suggested from experimental work, that inhibition of IL-18 might constitute a new therapeutic strategy in plaque stabilization.

	Appendix

Top Abstract Introduction Methods Results Discussion Appendix References

 
The PRIME Study Group
The PRIME study is organized under an agreement between INSERM and the Merck, Sharpe and Dohme-Chibret Laboratory, with the following participating laboratories: the Strasbourg MONICA Project, Strasbourg, France (D. Arveiler, B. Haas); the Toulouse MONICA Project, INSERM U558, Toulouse, France (J. Ferrières, J.B. Ruidavets); the Lille MONICA Project, INSERM U508, Lille, France (P. Amouyel, M. Montaye); the Department of Epidemiology and Public Health, Queen’s University Belfast, Northern Ireland (A. Evans, J. Yarnell); the Department of Atherosclerosis, SERLIA–INSERM U545, Lille, France (G. Luc, J.M. Bard); the Laboratory of Hematology, La Timone Hospital, Marseille, France (I. Juhan-Vague); the Laboratory of Endocrinology, INSERM U326, Toulouse, France (B. Perret); the Vitamin Research Unit, The University of Bern, Bern, Switzerland (F. Gey); the Trace Element Laboratory, Department of Medicine, Queen’s University Belfast, Northern Ireland (D. McMaster); the DNA Bank, INSERM U525/SC7, Paris, France (F. Cambien); and the Coordinating Center, INSERM U258, Villejuif, France (P. Ducimetière, P.Y. Scarabin, A. Bingham).

	Acknowledgments

 
Dr Blankenberg was supported by a grant of the Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France. We thank the following organizations, which allowed the recruitment of the PRIME subjects: the health screening centers organized by the Social Security of Lille (Institut Pasteur), Strasbourg, Toulouse, and Tourcoing; Occupational Medicine Services of Haute-Garonne, of the Urban Community of Strasbourg; the Association Inter-entreprises des Services Médicaux du Travail de Lille et environs; the Comité pour le Développement de la Médecine du Travail; the Mutuelle Générale des PTT du Bas-Rhin; the Laboratoire d’Analyses de l’Institut de Chimie Biologique de la Faculté de Médecine de Strasbourg; and the Department of Health (NI) and the Northern Ireland Chest Heart and Stroke Association. We are indebted to Susanne Prigge, Ruediger Walscheid, and Axel Thuy for determining the IL-18 measurements and to Margot Neuser for her graphical work.

	Footnotes

 
This article originally appeared Online on October 27, 2003 (Circulation. 2003;108:r115–r121).

	References

Top Abstract Introduction Methods Results Discussion Appendix References

 

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115–126.[Free Full Text]
   
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135–1143.[Abstract/Free Full Text]
   
3. Scarabin PY, Arveiler D, Amouyel P, et al. Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland: the PRIME study. Atherosclerosis. 2003; 166: 103–109.[CrossRef][Medline] [Order article via Infotrieve]
   
4. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347: 1557–1565.[Abstract/Free Full Text]
   
5. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107: 499–511.[Free Full Text]
   
6. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836–843.[Abstract/Free Full Text]
   
7. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol. 2003; 73: 213–224.[Abstract/Free Full Text]
   
8. Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995; 378: 88–91.[CrossRef][Medline] [Order article via Infotrieve]
   
9. Gupta S, Pablo AM, Jiang X, et al. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest. 1997; 99: 2752–2761.[Medline] [Order article via Infotrieve]
   
10. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995; 91: 2844–2850.[Free Full Text]
    
11. Mallat Z, Corbaz A, Scoazec A, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001; 104: 1598–1603.[Abstract/Free Full Text]
    
12. Mallat Z, Corbaz A, Scoazec A, et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res. 2001; 89: E41–E45.[CrossRef][Medline] [Order article via Infotrieve]
    
13. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res. 2002; 90: E34–E38.[CrossRef][Medline] [Order article via Infotrieve]
    
14. Gerdes N, Sukhova GK, Libby P, et al. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med. 2002; 195: 245–257.[Abstract/Free Full Text]
    
15. Blankenberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002; 106: 24–30.[Abstract/Free Full Text]
    
16. Yarnell JW. The PRIME study: classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland: Prospective Epidemiological Study of Myocardial Infarction. QJM. 1998; 91: 667–676.[Abstract/Free Full Text]
    
17. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994; 90: 583–612.[Abstract/Free Full Text]
    
18. Ducimetiere P, Ruidavets JB, Montaye M, et al. Five-year incidence of angina pectoris and other forms of coronary heart disease in healthy men aged 50–59 in France and Northern Ireland: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Int J Epidemiol. 2001; 30: 1057–1062.[Abstract/Free Full Text]
    
19. Luc G, Bard JM, Juhan-Vague I, et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME study. Arterioscler Thromb Vasc Biol. 2003; 23: 1255–1261.[Abstract/Free Full Text]
    
20. Hansson GK, Libby P, Schonbeck U, et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002; 91: 281–291.[Abstract/Free Full Text]
    
21. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000; 321: 199–204.[Abstract/Free Full Text]
    
22. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001; 103: 1813–1818.[Abstract/Free Full Text]
    
23. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107: 363–369.[Free Full Text]
    
24. Bickel C, Rupprecht HJ, Blankenberg S, et al. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002; 89: 901–908.[CrossRef][Medline] [Order article via Infotrieve]
    
25. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999; 99: 2079–2084.[Abstract/Free Full Text]
    
26. Lindmark E, Diderholm E, Wallentin L, et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001; 286: 2107–2113.[Abstract/Free Full Text]
    
27. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003; 107: 1579–1585.[Abstract/Free Full Text]
    

This article has been cited by other articles:

				R. R. S. Packard and P. Libby Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction Clin. Chem., January 1, 2008; 54(1): 24 - 38. [Abstract] [Full Text] [PDF]

				S. R. Thompson, D. Novick, C. J. Stock, J. Sanders, D. Brull, J. Cooper, P. Woo, G. Miller, M. Rubinstein, and S. E. Humphries Free Interleukin (IL)-18 Levels, and the Impact of IL18 and IL18BP Genetic Variation, in CHD Patients and Healthy Men Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2743 - 2749. [Abstract] [Full Text] [PDF]

				S. R. Thompson, P. A. McCaskie, J. P. Beilby, J. Hung, M. Jennens, C. Chapman, P. Thompson, and S. E. Humphries IL18 Haplotypes Are Associated with Serum IL-18 Concentrations in a Population-Based Study and a Cohort of Individuals with Premature Coronary Heart Disease Clin. Chem., December 1, 2007; 53(12): 2078 - 2085. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, J. Dallongeville, G. De Backer, S. Ebrahim, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) Eur. Heart J., October 1, 2007; 28(19): 2375 - 2414. [Full Text] [PDF]

				A. Zirlik, S. M. Abdullah, N. Gerdes, L. MacFarlane, U. Schonbeck, A. Khera, D. K. McGuire, G. L. Vega, S. Grundy, P. Libby, et al. Interleukin-18, the Metabolic Syndrome, and Subclinical Atherosclerosis: Results From the Dallas Heart Study Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 2043 - 2049. [Abstract] [Full Text] [PDF]

				A. Orozco, E. Gemmell, M. Bickel, and G.J. Seymour Interleukin 18 and Periodontal Disease J. Dent. Res., July 1, 2007; 86(7): 586 - 593. [Abstract] [Full Text] [PDF]

				S. Musaad and E. N. Haynes Biomarkers of Obesity and Subsequent Cardiovascular Events Epidemiol. Rev., May 10, 2007; (2007) mxm005v1. [Abstract] [Full Text] [PDF]

				N. P. Kadoglou, D. Perrea, F. Iliadis, N. Angelopoulou, C. Liapis, and M. Alevizos Exercise Reduces Resistin and Inflammatory Cytokines in Patients With Type 2 Diabetes Diabetes Care, March 1, 2007; 30(3): 719 - 721. [Full Text] [PDF]

				T. M. Frayling, S. Rafiq, A. Murray, A. J. Hurst, M. N. Weedon, W. Henley, S. Bandinelli, A.-M. Corsi, L. Ferrucci, J. M. Guralnik, et al. An Interleukin-18 Polymorphism Is Associated With Reduced Serum Concentrations and Better Physical Functioning in Older People J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2007; 62(1): 73 - 78. [Abstract] [Full Text] [PDF]

				W. Koenig and N. Khuseyinova Biomarkers of Atherosclerotic Plaque Instability and Rupture Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 15 - 26. [Abstract] [Full Text] [PDF]

				W. Koenig, N. Khuseyinova, J. Baumert, B. Thorand, H. Loewel, L. Chambless, C. Meisinger, A. Schneider, S. Martin, H. Kolb, et al. Increased Concentrations of C-Reactive Protein and IL-6 but not IL-18 Are Independently Associated With Incident Coronary Events in Middle-Aged Men and Women: Results From the MONICA/KORA Augsburg Case-Cohort Study, 1984-2002 Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2745 - 2751. [Abstract] [Full Text] [PDF]

				C. Vlachopoulos, K. Aznaouridis, N. Ioakeimidis, K. Rokkas, C. Vasiliadou, N. Alexopoulos, E. Stefanadi, A. Askitis, and C. Stefanadis Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease Eur. Heart J., November 2, 2006; 27(22): 2640 - 2648. [Abstract] [Full Text] [PDF]

				S. Blankenberg and S. Yusuf The Inflammatory Hypothesis: Any Progress in Risk Stratification and Therapeutic Targets? Circulation, October 10, 2006; 114(15): 1557 - 1560. [Full Text] [PDF]

				T. K. Tso, W.-N. Huang, H.-Y. Huang, and C.-K. Chang Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosus Rheumatology, September 1, 2006; 45(9): 1148 - 1153. [Abstract] [Full Text] [PDF]

				S. Blankenberg, M. J. McQueen, M. Smieja, J. Pogue, C. Balion, E. Lonn, H. J. Rupprecht, C. Bickel, L. Tiret, F. Cambien, et al. Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study Circulation, July 18, 2006; 114(3): 201 - 208. [Abstract] [Full Text] [PDF]

				S. Blankenberg, T. Godefroy, O. Poirier, H. J. Rupprecht, S. Barbaux, C. Bickel, V. Nicaud, R. Schnabel, F. Kee, C. Morrison, et al. Haplotypes of the Caspase-1 Gene, Plasma Caspase-1 Levels, and Cardiovascular Risk Circ. Res., July 7, 2006; 99(1): 102 - 108. [Abstract] [Full Text] [PDF]

				L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Circulation, June 20, 2006; 113(24): e873 - e923. [Abstract] [Full Text] [PDF]

				L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke, June 1, 2006; 37(6): 1583 - 1633. [Abstract] [Full Text] [PDF]

				R. S. Vasan Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations Circulation, May 16, 2006; 113(19): 2335 - 2362. [Full Text] [PDF]

				S G Baidya and Q-T Zeng Helper T cells and atherosclerosis: the cytokine web Postgrad. Med. J., December 1, 2005; 81(962): 746 - 752. [Abstract] [Full Text] [PDF]

				G. P. Van Guilder, G. L. Hoetzer, D. T. Smith, H. M. Irmiger, J. J. Greiner, B. L. Stauffer, and C. A. DeSouza Endothelial t-PA release is impaired in overweight and obese adults but can be improved with regular aerobic exercise Am J Physiol Endocrinol Metab, November 1, 2005; 289(5): E807 - E813. [Abstract] [Full Text] [PDF]

				Z. Mallat, Ph. G. Steg, J. Benessiano, M.-L. Tanguy, K. A. Fox, J.-P. Collet, O. H. Dabbous, P. Henry, K. F. Carruthers, A. Dauphin, et al. Circulating Secretory Phospholipase A2 Activity Predicts Recurrent Events in Patients With Severe Acute Coronary Syndromes J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1249 - 1257. [Abstract] [Full Text] [PDF]

B. Thorand, H. Kolb, J. Baumert, W. Koenig, L. Chambless, C. Meisinger, T. Illig, S. Martin, and C. Herder Elevated Levels of Interleukin-18 Predict the Development of Type 2 Diabetes: Results From the MONICA/KORA Augsburg Study, 1984-2002 Diabetes, October 1, 2005;